CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for hVIVO PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

hVIVO PLC
42 New Road
Phone: +44 2890737900p:+44 2890737900 LONDON, E1 2AX  United Kingdom Ticker: HVOHVO
Business Summary
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8741 Management services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Cathal M.Friel 59 2/24/2022 1/17/2020
Chief Executive Officer, Executive Director YaminMohammed Khan 53 2/24/2022 10/13/2021
Chief Financial Officer, Executive Director StephenPinkerton 59 10/18/2022 10/18/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Cardinal Systems SAS
HVO
Kinesis Pharma BV
5 additional Business Names available in full report.

General Information
Number of Employees: 274 (As of 12/31/2023)
Outstanding Shares: 680,371,877 (As of 12/31/2023)
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024